Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR3LibHERty: Trastuzumab-deruxtecan in HR+, HER2 Low Metastatic Breast Cancer
NCT06680596Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jul 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Unicancer. Started Jul 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06680596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680596.